Steven Braunstein, MD
Ophthalmology · North Bergen, NJNPI 1821182494
Payments from drug & device makers
Across 72 payments — averaging $65.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Bausch & Lomb Americas Inc.$645
- Alcon$517
- Sun Pharmaceutical Industries Inc.$306
- AbbVie$290
- Aerie Pharmaceuticals, Inc.$138
- plus $726 from 11 others
What the payments were for
- Food & beverage$4,687100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 15 | $2,064 |
| Bausch & Lomb Americas Inc. | 16 | $645 |
| Alcon | 9 | $517 |
| Sun Pharmaceutical Industries Inc. | 8 | $306 |
| AbbVie(2 entities) | 7 | $290 |
| Aerie Pharmaceuticals, Inc. | 2 | $138 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $135 |
| NEW World Medical,inc. | 1 | $133 |
| Tarsus Pharmaceuticals, Inc. | 2 | $127 |
| Oyster Point Pharma, Inc. | 1 | $118 |
| Biotissue Holdings Inc. | 1 | $83 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $42 |
| Menicon America Inc | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Sight Sciences, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDoseTR$437
- iDose$338
- iStent inject W$315
- Photrexa$313
- iStent inject Trabecular Micro-Bypass Stent System$276
- VYZULTA$237
- enVista MX60 IOL$227
- CEQUA$225
- iStent$178
- KXL System$160
- IACCESS$154
- Voyager DSLT$150
- iStent Infinite$148
- Kahook Dual Blade$133
- Clearpath$133
- Ahmed Glaucoma Valve$133
- Streamline$133
- enVista Aspire IOL$125
- Rhopressa$125
- Rocklatan$125
How this compares
$4,687 in reported general payments places this provider in the 75th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 123 | $62,082 |
| Restasis MultidoseCyclosporine | 79 | $48,968 |
| RestasisCyclosporine | 61 | $42,663 |
| ProlensaBromfenac Sodium | 73 | $24,654 |
| Latanoprost | 2,380 | $21,992 |
| XiidraLifitegrast | 21 | $19,111 |
| RhopressaNetarsudil Mesylate | 54 | $18,839 |
| CombiganBrimonidine Tartrate/Timolol | 34 | $14,741 |
| VyzultaLatanoprostene Bunod | 27 | $14,441 |
| Prednisolone Acetate | 287 | $13,952 |
| Alphagan PBrimonidine Tartrate | 40 | $13,857 |
| TyrvayaVarenicline Tartrate | 20 | $13,280 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 836 | $10,886 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 61 | $10,136 |
| Cyclosporine | 48 | $9,889 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis Multidose, Restasis, Combigan, Alphagan P | $290 | $182,312337 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $645 | $33,55248 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $42 | $24,65473 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $138 | $18,83954 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $118 | $13,28020 claims |
| AlconSimbrinza | $517 | $6,34733 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in North Bergen
- Patrick HigginsBloomfield$16.7M
- Jai ParekhWoodland Park$2.1M
- Eric MannDover$860K
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Luis Gonzalez GonzalezTeaneck$727K
- Cynthia MatossianPennington$726K
- Charles CraneSouth Orange$582K
- Albert KhouriNewark$542K
- Brett BieloryRutherford$477K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.